Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

被引：6

作者：

Cluzeau, Thomas ^{[1
]}

Mounier, Nicolas ^{[2
]}

Richez, Valentine ^{[3
]}

Karsenti, Jean-Michel ^{[2
]}

Legrand, Faezeh ^{[2
]}

Mannone, Lionel ^{[2
]}

Vinti, Henri ^{[2
]}

Legros, Laurence ^{[4
]}

Gastaud, Lauris ^{[5
]}

Thyss, Antoine ^{[5
]}

Garnier, Georges ^{[6
]}

Re, Daniel ^{[7
]}

Montagne, Nathalie ^{[8
]}

Gutnecht, Jean ^{[9
]}

Auberger, Patrick ^{[10
]}

Raynaud, Sophie ^{[11
]}

Cassuto, Jill-Patrice ^{[2
]}

机构：

[1] CHU Archet, Serv Hematol, Nice, France

[2] Hop Archet, Serv Hematol Clin, Nice, France

[3] CHU Nice, Dept Hematol, Nice, France

[4] Hop Archet 1 151, Nice, France

[5] Ctr Antoine Lacassagne, F-06054 Nice, France

[6] CHPG, Serv Med Interne, Monaco, Monaco

[7] CH Antibes, Antibes, France

[8] CH Cannes, Serv Med Interne, Cannes, France

[9] Ctr Hosp Intercommunal Frejus St Raphael, Serv Med Interne, Frejus, France

[10] Fac Med Nice, INSERM, U1065, Team 2,Equipe Labellisee LNCC, F-06034 Nice, France

[11] Univ Nice, CHU Archet, Hematol Lab, Nice, France

来源：

关键词：

D O I：

10.1182/blood.V120.21.2813.2813

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2813

引用

页数：2